2015 - Porteur du projet : Dr MASSON Murielle - Partenaires : Pr BIREMBAUT Philippe, Pr CLAVEL Christine, Dr JUNG Alain, Pr MOUGIN Christiane, Pr PRETET Jean-Luc, Pr VALMARY-DEGANO Séverine

Implication de la voie Hippo dans la carcinogenese virale induite par les HPV

2014 - Porteur du projet : Dr MASSON Murielle

Implication de la voie Hippo dans la carcinogenèse induite par les papillomavirus humains (HPV).

2013 - Porteur du projet : Dr MASSON Murielle

Publications

Tracing endogenous proteins in living cells through electrotransfer of mRNA encoding chromobodies.

Juncker T, Richert L, Masson M, Zuber G, Chatton B, Donzeau M

Biotechnol J. 2024 02;19(2):e2300548

The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.

Riegel G, Orvain C, Recberlik S, Spaety ME, Poschet G, Venkatasamy A, Yamamoto M, Nomura S, Tsukamoto T, Masson M, Gross I, Le Lagadec R, Mellitzer G, Gaiddon C

Cancer Lett. 2024 01 28;:216671

The E2F4/p130 Repressor Complex Cooperates with Oncogenic ΔNp73α To Inhibit Gene Expression in Human Papillomavirus 38 E6/E7-Transformed Keratinocytes and in Cancer Cells.

Taverniti V, Krynska H, Venuti A, Straub ML, Sirand C, Lohmann E, Romero-Medina MC, Moro S, Robitaille A, Negroni L, Martinez-Zapien D, Masson M, Tommasino M, Zanier K

mSphere. 2023 03 8;:e0005623

Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair.

Bruyere D, Roncarati P, Lebeau A, Lerho T, Poulain F, Hendrick E, Pilard C, Reynders C, Ancion M, Luyckx M, Renard M, Jacob Y, Twizere JC, Peiffer R, Peulen O, Delvenne P, Hubert P, McBride A, Gillet N, Masson M, Herfs M

Theranostics. 2023 01 31;13(3):1130-1149

Master mitotic kinases regulate viral genome delivery during papillomavirus cell entry.

Rizzato M, Mao F, Chardon F, Lai KY, Villalonga-Planells R, Drexler HCA, Pesenti ME, Fiskin M, Roos N, King KM, Li S, Gamez ER, Greune L, Dersch P, Simon C, Masson M, Van Doorslaer K, Campos SK, Schelhaas M

Nat Commun. 2023 01 23;14(1):355

High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression.

Poirson J, Suarez IP, Straub ML, Cousido-Siah A, Peixoto P, Hervouet E, Foster A, Mitschler A, Mukobo N, Chebaro Y, Garcin D, Recberlik S, Gaiddon C, Altschuh D, Nominé Y, Podjarny A, Trave G, Masson M

J Virol. 2022 Apr 27;:e0187521

HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources.

Lebeau A, Bruyere D, Roncarati P, Peixoto P, Hervouet E, Cobraiville G, Taminiau B, Masson M, Gallego C, Mazzucchelli G, Smargiasso N, Fleron M, Baiwir D, Hendrick E, Pilard C, Lerho T, Reynders C, Ancion M, Greimers R, Twizere JC, Daube G, Schlecht-Louf G, Bachelerie F, Combes JD, Melin P, Fillet M, Delvenne P, Hubert P, Herfs M

Nat Commun. 2022 Feb 28;13(1):1076

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S

Cancers (Basel). 2021 Jun 18;13(12):

Structure of high-risk papillomavirus type 31 E6 oncogenic protein and characterization of E6/E6AP/p53 complex formation.

Conrady MC, Suarez I, Gogl G, Frecot DI, Bonhoure A, Kostmann C, Cousido-Siah A, Mitschler A, Lim J, Masson M, Iftner T, Stubenrauch F, Trave G, Simon C

J Virol. 2020 Oct 28;:

Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.

Stoessel A, Groysbeck N, Guyot L, Barret L, Nominé Y, Nguekeu-Zebaze L, Bender A, Voilquin L, Lutz T, Pallaoro N, Blocat M, Deville C, Masson M, Zuber G, Chatton B, Donzeau M

Bioconjug. Chem.. 2020 Sep 30;:

Human papillomavirus type 16 antagonizes IRF6 regulation of IL-1β.

Ainouze M, Rochefort P, Parroche P, Roblot G, Tout I, Briat F, Zannetti C, Marotel M, Goutagny N, Auron P, Traverse-Glehen A, Lunel-Potencier A, Golfier F, Masson M, Robitaille A, Tommasino M, Carreira C, Walzer T, Henry T, Zanier K, Trave G, Hasan UA

PLoS Pathog.. 2018 Aug 8;14(8):e1007158

Mapping the interactome of HPV E6 and E7 oncoproteins with the Ubiquitin-Proteasome System.

Poirson J, Biquand E, Straub ML, Cassonnet P, Nominé Y, Jones L, van der Werf S, Travé G, Zanier K, Jacob Y, Demeret C, Masson M

FEBS J.. 2017 Aug;:

Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.

Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande Pol S, Podjarny A, Travé G, Zanier K

Nature. 2016 Jan;529(7587):541-5

Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.

Bonetta AC, Mailly L, Robinet E, Trave G, Masson M, Deryckere F

Biochem Biophys Res Commun. 2015 Aug 1. pii: S0006-291X(15)30375-2

Quantifying domain-ligand affinities and specificities by high-throughput holdup assay.

Vincentelli R, Luck K, Poirson J, Polanowska J, Abdat J, Blemont M, Turchetto J, Iv F, Ricquier K, Straub ML, Forster A, Cassonnet P, Borg JP, Jacob Y, Masson M, Nomine Y, Reboul J, Wolff N, Charbonnier S, Trave G

Nat Methods. 2015 Aug;12(8):787-93

Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.

Ramirez J, Poirson J, Foltz C, Chebaro Y, Schrapp M, Meyer A, Bonetta A, Forster A, Jacob Y, Masson M, Deryckere F, Trave G

Angew Chem Int Ed Engl. 2015 May 27

Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1.

Fournane S, Charbonnier S, Chapelle A, Kieffer B, Orfanoudakis G, Trave G, Masson M, Nomine Y

J Mol Recognit. 2011 Jul-Aug;24(4):511-23

Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.

Bernard X, Robinson P, Nomine Y, Masson M, Charbonnier S, Ramirez-Ramos JR, Deryckere F, Trave G, Orfanoudakis G

PLoS One. 2011;6(10):e25981

Putting into practice domain-linear motif interaction predictions for exploration of protein networks.

Luck K, Fournane S, Kieffer B, Masson M, Nomine Y, Trave G

PLoS One. 2011;6(11):e25376

E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo.

Zanier K, Ruhlmann C, Melin F, Masson M, Ould M'hamed Ould Sidi A, Bernard X, Fischer B, Brino L, Ristriani T, Rybin V, Baltzinger M, Vande Pol S, Hellwig P, Schultz P, Trave G

J Mol Biol. 2010 Feb 12;396(1):90-104

Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity.

Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, Trave G, Burk RD

PLoS One. 2010 Sep 17;5(9). pii: e12816.

A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.

Ristriani T, Fournane S, Orfanoudakis G, Trave G, Masson M

Oncogene. 2009 Feb 5;28(5):762-72

Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.

Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F, Sibler AP, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Trave G

Mol Cell. 2006 Mar 3;21(5):665-78.

Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.

Lagrange M, Charbonnier S, Orfanoudakis G, Robinson P, Zanier K, Masson M, Lutz Y, Trave G, Weiss E, Deryckere F

J Gen Virol. 2005 Apr;86(Pt 4):1001-7.

Nucleocytoplasmic shuttling of antigen in mammalian cells conferred by a soluble versus insoluble single-chain antibody fragment equipped with import/export signals.

Sibler AP, Nordhammer A, Masson M, Martineau P, Trave G, Weiss E

Exp Cell Res. 2003 Jun 10;286(2):276-87.